Heisterkamp, N., Groffen, J., Warburton, D
The increasing popularity of GLP-1 drugs is reshaping the doctor-patient relationship, with patients often arriving at appointments with specific treatment preferences influenced by social media and advertising
Part of the PlexusDx Education Hub, our neutral guide to GLP-1 telehealth programs and the genetics that underlie them
In a study in which juvenile dogs received lisdexamfetamine dimesylate for 6 months beginning at 10 weeks of age, decreased bodyweight gain was seen at all doses tested (2, 5, and 12 mg/kg/day, which are approximately 0.5, 1, and 3 times the maximum recommended human daily dose on a mg/m2 basis for a child)